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pplication of cells to restore damaged myocardium or
educe further functional deterioration represents an impor-
ant therapeutic modality for the treatment of patients with
yocardial infarction and heart failure. In pre-clinical mod-
ls of myocardial infarction, delivery of bone marrow–
erived progenitor cells, skeletal myoblasts, or mesenchymal
tem cells improves functional recovery of infracted myo-
ardium (1). Several clinical trials have also shown improved
eft ventricular function in patients receiving cell therapy
2). However, other studies have not shown similar im-
rovement in cardiac function following cell delivery (2).
See page 794
he contradictory results could have been due to a number
f factors influencing the therapeutic application of cells.
hese include the cell type used, cell dose, timing of
elivery, site of delivery, and functional potential of cells.
ata from a variety of studies have shown that only 1% to
% of the administered cells are recruited at the infarct site.
he retention of cells in the target tissue is extremely low
hen delivered by the intravenous rout (3). A higher initial
eposition of cells is achieved by intramyocardial delivery
3). Subsequent cell death of injected cells reduces engraft-
ent efficiency when measured at several days after delivery.
greater efficacy is achieved at higher cell dose, suggesting
hat a higher engraftment of cells may be required for
ptimum efficacy. However, high cell dose also produces
arger systemic circulation, which increases the safety con-
erns. Thus, the inability to achieve desired cell homing and
ngraftment for optimum efficacy has been recognized as a
undamental issue for cell-based therapies. Pre-clinical stud-
es, where efficacy of cell therapy has been consistently
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-a
ions or the American College of Cardiology.
From Saint Joseph’s Translational Research Institute, Atlanta, Georgia.emonstrated, are performed using younger animals with-
ut cardiovascular disease risk factors. In clinical setting, the
atients receiving autologous cells, the cell engraftment is
reatly impaired. It has been found that the circulating
umber of progenitor cells is greatly reduced in patients
ith cardiovascular disease risk factors (4,5). When number
f risk factors is higher, there is greater reduction of
irculating progenitor cells. Circulating autologous endo-
helial progenitor cells correlate with Framingham coronary
isk score (6). Furthermore, the progenitor cells from
atients with cardiovascular disease risk factor are found to
e dysfunctional. For example, progenitor cells isolated
rom patients with diabetes, heart disease, stroke, and renal
isease exhibit impaired homing capacity (7). Thus, en-
bling technologies that can promote homing of cells at the
arget site may promote efficacy of the delivered cells.
Several different experimental approaches for a greater
oming and engraftment of cells at the target site are under
nvestigation (7,8). These include pre-treatment of cells
ith pharmacological agents such as estrogen, statins, nitric
xide donors and endothelial nitric oxide synthase activators
hat improve the impaired cellular mechanisms leading to a
reater homing; genetic engineering of cells by Akt gene
ransfer, local administration of endothelial progenitor cell
ecruitment chemokine SDF-1, and implantation of cells
ncorporated of in a matrix scaffold such as fibrin or
anofibers. These methods have produced increased pro-
enitor functions and their efficacy in pre-clinical models of
schemia. Their utility for cell enrichment at the target site
s yet to be tested in the clinical settings.
In the study published in this issue of JACC: Cardiovas-
ular Interventions, Kyrtatos et al. (9) have used endothelial
rogenitor cells tagged with iron oxide superparamagnetic
anoparticles to enhance cell accumulation by magnetic
ctuation. In recent years, nanoparticles have been success-
ully used for drug delivery and tracking of cells in vivo. The
nvestigators first tested the superparamagnetic iron oxide
anoparticle-tagged cells by using an in vitro simulation
ystem and demonstrated a 6-fold increase in the number of
ells at the site of magnet placement after 1 h. For
chievement of directed cell accumulation, the investigators
eveloped a special magnet to enable orientation for rat
arotid artery. In vivo testing produced about 5-fold higher
ell number in the injured carotid artery at the site of the
agnetic field application. Based on these data, the inves-
igators have concluded that the study represents a proof of
oncept for the induction of cell homing using the nano-
article tags. The experimental results suggest that this
ould be a potential approach for enhancement of cell
oming, at least in tissues that can be accessible by external
agnetic force.
The study, however, has a number of limitations. By
electing Endorem as the tagging material, the investigators
ssume that Endorem may be safer than the other forms of
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804uperparamagnetic iron oxide nanoparticles. Although, En-
orem is approved, by the U.S. Food and Drug Adminis-
ration, for cell tracking by magnetic resonance imaging, its
afety for therapeutic use is yet to be determined. The cell
iability and functional activity following the ingestion of
anoparticles and magnetic force application are important
ssues. Extended magnetic application clearly leads to cell
eath as reported in Figure 2 of the article by Kyrtatos et al. (9).
his is consistent with the known deleterious effects of iron
anoparticles on cellular structures. Therefore, functional ac-
ivities of the cells containing nanoparticles need to be dem-
nstrated. Cellular activities such as cell proliferation, migra-
ion, adhesion, spreading, in vitro angiogenesis, and cytokine
ene expression could be used to assess the effects of nanopar-
icles and magnetic force on cell functionality.
Although, the magnetic actuation induced a 5-fold in-
rease in the number of cells at the injured site, it is not
nown whether an initial increase in cell number of this
agnitude is indeed adequate to improve vascular function
nd efficacy. The confocal microscopic studies were per-
ormed at 24 h after cell delivery. These data indicate
ncreased cell accumulation in the injured artery at the site
f the magnetic field. Demonstration of vascular coverage,
ell morphology, and expression of endothelial cell surface
arkers over a period of several days to weeks must be
erformed. It is important to note that a continuous
eduction in cell survival and localization at the target site
ccurs over time (3). Therefore, the ability of cells to survive,
ngraft, and produce accelerated re-endothelialization needs to
e demonstrated. The efficacy of the engrafted cells needs to be
etermined by improvement in vascular function by ex vivo and
n vivo vascular reactivity.
The use of the magnetic field for cell attraction also
epresents a significant limitation for its application to target
issues localized deeper in the body. A greater magnetic
orce will be required for targeting tissues such as those of
he heart. Therefore, achievement of the cell engraftment
ecessary for therapeutic effects by using a “safe magnet
orce” would be challenging. In the current study, the
nvestigators did not determine the impact of magnetic field
n the pathophysiology of the injured carotid artery. A good
xperimental control would have been to determine the
ffects of the magnetic field alone on the injured carotid
rtery. For example, it was not determined if the application nf the magnetic force to injured artery leads to increased
hrombosis, which may impact cell accumulation.
Besides the limitations and the preliminary nature of the
tudy using iron oxide paramagnetic nanoparticle technol-
gy, it is important to further assess its utility along with
ther potentially new enabling technologies currently under
nvestigation for the improvement of cell homing and
ngraftment. This is particularly important for intravenous
dministration of cells, a most convenient rout of cell
elivery. Greater than 90% of the cells end up in the lung
ollowing intravenous delivery. The number of cells found in
he heart after a few weeks are undetectable. There lies the
hallenge to enabling technologies for cell homing and
ngraftment.
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